MA33052B1 - Variants de liaison anti-albumine sérique améliorés - Google Patents

Variants de liaison anti-albumine sérique améliorés

Info

Publication number
MA33052B1
MA33052B1 MA34105A MA34105A MA33052B1 MA 33052 B1 MA33052 B1 MA 33052B1 MA 34105 A MA34105 A MA 34105A MA 34105 A MA34105 A MA 34105A MA 33052 B1 MA33052 B1 MA 33052B1
Authority
MA
Morocco
Prior art keywords
serum albumin
contrasts
albumin enhancer
antagonist
antagonist serum
Prior art date
Application number
MA34105A
Other languages
Arabic (ar)
English (en)
Inventor
Angelis Elena De
Carolyn Enever
Haiqun Liu
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33052B1 publication Critical patent/MA33052B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des variants améliorés du domaine variable unique DOM7h-14 de l'immunoglobuline anti-albumine sérique, ainsi que des ligands et des conjugués de médicaments contenant de tels variants, des compositions, des acides nucléiques, des vecteurs et des hôtes.
MA34105A 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés MA33052B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16399009P 2009-03-27 2009-03-27
PCT/EP2010/052007 WO2010094722A2 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Publications (1)

Publication Number Publication Date
MA33052B1 true MA33052B1 (fr) 2012-02-01

Family

ID=42306619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34105A MA33052B1 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Country Status (23)

Country Link
US (2) US9175071B2 (fr)
EP (1) EP2398825B1 (fr)
JP (1) JP5766616B2 (fr)
KR (1) KR101820968B1 (fr)
CN (2) CN105061593B (fr)
AR (1) AR075506A1 (fr)
AU (2) AU2010215481C1 (fr)
BR (1) BRPI1008705B1 (fr)
CA (1) CA2753130C (fr)
CL (1) CL2011002023A1 (fr)
CO (1) CO6450689A2 (fr)
DO (1) DOP2011000269A (fr)
EA (1) EA027866B1 (fr)
ES (1) ES2654929T3 (fr)
IL (1) IL214481A0 (fr)
MA (1) MA33052B1 (fr)
MX (1) MX2011008752A (fr)
PE (1) PE20120170A1 (fr)
SG (1) SG173488A1 (fr)
TW (1) TW201042041A (fr)
UY (1) UY32452A (fr)
WO (1) WO2010094722A2 (fr)
ZA (1) ZA201105658B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
WO2010094723A2 (fr) 2009-02-19 2010-08-26 Glaxo Group Limited Variants de liaison anti-albumine sérique améliorés
TW201100104A (en) * 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
JP2013538566A (ja) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
EA201390450A1 (ru) * 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
KR102729723B1 (ko) * 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
JP7519774B2 (ja) 2016-12-09 2024-07-22 グリックニック インコーポレイテッド 多価ｆｃ化合物を用いる炎症性疾患の治療方法
PT3583125T (pt) 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Proteínas de fusão ao domínio de ligação à albumina
JP7130678B2 (ja) 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
WO2018224439A1 (fr) * 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-hsa
EP3807311A4 (fr) * 2018-04-24 2022-01-26 National Research Council of Canada Anticorps de liaison à l'albumine sérique pour extension de demi-vie réglable de produits biologiques
KR102204315B1 (ko) * 2018-11-16 2021-01-18 한국세라믹기술원 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도
CA3201560A1 (fr) * 2020-12-08 2022-06-16 David Campbell Compositions et procedes d'extension de demi-vie
WO2024097639A1 (fr) * 2022-10-31 2024-05-10 Modernatx, Inc. Anticorps se liant à hsa et protéines de liaison et leurs utilisations
EP4665755A1 (fr) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12459994B2 (en) * 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713272A1 (de) 1997-03-29 1998-10-08 Junghans Uhren Gmbh Zeitzonen-Uhr
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1517921B1 (fr) 2002-06-28 2006-06-07 Domantis Limited Ligands a specificite double et avec une demi-vie augmentee
ES2351509T3 (es) 2004-03-24 2011-02-07 Domantis Limited Secuencia lider universal de gas1.
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
RU2007119989A (ru) 2004-12-02 2009-01-10 Домантис Лимитед (Gb) Композиции, слитые конструкции и конъюгаты plad домена
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA201100653A1 (ru) 2008-11-26 2011-12-30 Глаксо Груп Лимитед Лиганды, связывающиеся с интерлейкином-13 (il-13)

Also Published As

Publication number Publication date
EP2398825B1 (fr) 2017-10-25
KR20110127224A (ko) 2011-11-24
EA201171067A1 (ru) 2012-02-28
DOP2011000269A (es) 2011-12-31
KR101820968B1 (ko) 2018-01-23
CN102405232A (zh) 2012-04-04
IL214481A0 (en) 2011-09-27
US20160075774A1 (en) 2016-03-17
AU2010215481C1 (en) 2015-06-04
AU2014202764B2 (en) 2016-07-07
EP2398825A2 (fr) 2011-12-28
AU2010215481A1 (en) 2011-08-25
CL2011002023A1 (es) 2012-04-09
EA027866B1 (ru) 2017-09-29
UY32452A (es) 2010-09-30
MX2011008752A (es) 2011-09-06
AU2010215481B2 (en) 2014-02-20
BRPI1008705A2 (pt) 2016-03-08
SG173488A1 (en) 2011-09-29
US20110300158A1 (en) 2011-12-08
AR075506A1 (es) 2011-04-06
PE20120170A1 (es) 2012-03-21
JP2012517819A (ja) 2012-08-09
US9175071B2 (en) 2015-11-03
TW201042041A (en) 2010-12-01
WO2010094722A3 (fr) 2011-01-13
BRPI1008705B1 (pt) 2021-05-25
CN105061593A (zh) 2015-11-18
CA2753130C (fr) 2020-07-14
JP5766616B2 (ja) 2015-08-19
CA2753130A1 (fr) 2010-08-26
US9751935B2 (en) 2017-09-05
CN102405232B (zh) 2015-08-19
CN105061593B (zh) 2018-08-03
WO2010094722A2 (fr) 2010-08-26
ZA201105658B (en) 2012-05-25
AU2014202764A1 (en) 2014-06-12
CO6450689A2 (es) 2012-05-31
ES2654929T3 (es) 2018-02-15

Similar Documents

Publication Publication Date Title
MA33052B1 (fr) Variants de liaison anti-albumine sérique améliorés
MA33051B1 (fr) Variants de liaison anti-albumine serique ameliores
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
IN2012DN00640A (fr)
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EP2152290A4 (fr) Méthodes pour administrer des anticorps anti-il-5
EP2560684A4 (fr) Échafaudages multimériques à base de domaine de fibronectine de type iii
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
EA201170441A1 (ru) Терапевтические противовирусные пептиды
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
CR20110472A (es) Variantes de unión a anti-albumina de suero mejoradas
CY1116251T1 (el) Συστηματα michael ως αναστολεις τρανσγλουταμινασων
MA37838A1 (fr) Immunoconjugués comprenant des anticorps anti-cd22
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.